I Human Management Plan: Impaired Memory – Dementia, Alzheimer’s
I Human Management Plan: Impaired Memory – Dementia, Alzheimer’s
I Human Management Plan: Impaired Memory – Dementia, Alzheimer’s
Management plan for individuals presented with imparted memory related to dementia or Alzheimer’s involves various components, including diagnostic tests, medications, referrals, client education, and follow-up care.
ORDER A CUSTOMIZED, PLAGIARISM-FREE I Human Management Plan: Impaired Memory – Dementia, Alzheimer’s HERE
Thanks for stopping by this assessment. We can assist you in completing it and other subsequent ones. Our expert writers will comprehensively review instructions, synthesize external evidence sources, and customize an A-grade paper for YOU!!!
Diagnostic Tests
The client, J.L is presented with memory loss. Thus, various diagnostic tests should be conducted to determine the health condition contributing to these symptoms. First, brain imaging should be conducted to diagnose this client with dementia or Alzheimer’s disease. This test uses computed tomography (CT) or magnetic resonance imaging (MRI) to detect other conditions with symptoms that resemble Alzheimer’s but requires different treatment intervention. The second test is the Cerebrospinal fluid (CSF) test. This test is conducted to detect changes in CSF levels caused by Alzheimer’s disease. The early stages of Alzheimer’s disease may alter CSF levels of various markers, including tau and beta-amyloid. Furthermore, clinicians use the Quick Dementia Rating System (QDRS) to assess individual’s cognitive impairment (Porsteinsson et al., 2021). Lastly, a blood test would be conducted to determine the progression of Alzheimer’s disease (AD).
Medications
Upon being diagnosed with Alzheimer’s disease the client would be prescribed medications to manage presented symptoms, including memory loss. According to Porsteinsson et al. (2021), the FDA has approved various drug classes, including monoclonal antibodies, γ-secretase inhibitors, γ-secretase modulators, and BACE inhibitors, nicotinic agonists, RAGE inhibitors, and 5HT6 antagonists in treating AD. The client would be prescribed donepezil HCL 5mg orally daily. Being a cholinesterase inhibitor this medication will improve the client’s memory, enhancing cognitive functioning.
Referrals
Individuals diagnosed with AD require comprehensive care. In most cases, AD is accompanied by the manifestation of neuropsychological symptoms, including depression, agitation, anxiety, sleep disorders, hallucinations, delusions, apathy, psychosis, and delirium (Phan et al., 2019). According to Phan et al. (2019), using pharmacotherapy to manage these neuropsychological symptoms in patients with AD results in superior health outcomes. Therefore, the client should be referred to a psychiatrist for the management of neuropsychological symptoms. Phan et al. (2019) recommend psychotropic medications as the first-line treatment for neuropsychological symptoms following a thorough benefit to risk assessment. This treatment intervention will remit presented neuropsychological symptoms, improving the patient’s functioning capacity and quality of life.
Client Education
Patient education mainly targets family members or caregivers. It aims at creating awareness on how to cope with a patient’s condition. According to Deb et al. (2019), patients with AD require comprehensive care and support. Thus, the family members would be educated on the significance of home safety modifications, personal care, safety services, adult day care, and eventually full-time residential services in managing the client’s condition.
Follow-Up
The client would be scheduled for a follow-up clinic annually. During the follow-up clinic, a healthcare provider monitor’s patient’s progress and personal need to be addressed such as proving hearing aids. Addressing these needs enables a patient to live a longer, happier, and fuller life.
Overall, a treatment plan for a patient presented with memory loss consists of various components, including diagnostic tests, mediations, referral, patient education, and follow-up. These elements contribute to the management of presented clinical manifestations, enabling an individual to live a longer, happier, and fuller life.
References
Deb, A., Thornton, J. D., Sambamoorthi, U., & Innes, K. (2017). The direct and indirect cost of managing Alzheimer’s disease and related dementias in the United States. Expert review of pharmacoeconomics & outcomes research, 17(2), 189-202. Doi: 10.1080/14737167.2017.1313118.
Phan, S. V., Osae, S., Morgan, J. C., Inyang, M., & Fagan, S. C. (2019). Neuropsychiatric symptoms in dementia: considerations for pharmacotherapy in the USA. Drugs in R&D, 19(2), 93-115.
Porsteinsson, A. P., Isaacson, R. S., Knox, S., Sabbagh, M. N., & Rubino, I. (2021). Diagnosis of early alzheimer’s disease: Clinical practice in 2021. The Journal of Prevention of Alzheimer’s disease, 8(3), 371-386. http://dx.doi.org/10.14283/jpad.2021.23
ORDER A CUSTOMIZED, PLAGIARISM-FREE I Human Management Plan: Impaired Memory – Dementia, Alzheimer’s HERE
Management plan for I-Human (Janet Riley) Impaired Memory – Dementia, Alzheimer’s
Management Plan: Create a comprehensive treatment plan using professional language. Include at least one appropriate, evidence-based, scholarly source to support your decisions. Include the following components:
a. diagnostic tests
b. medications – write an actual prescription appropriate to the final diagnosis
c. suggested consults/referrals
d. client education
e. follow-up
please use clinical practice guideline and peer reviewed evidenced based journal from the United States only